Introduction to the RMA – Repatriation Medical Authority

for amyopathic dermatomyositis only, being treated with hydroxyurea for a continuous period of at least the six months before the clinical worsening of dermatomyositis; or being treated with a drug which is associated in the individual with: the worsening of dermatomyositis during drug therapy; and either ................
................